We are delighted to announce that OHMX.bio is now part of the anacura family! 🙌
As a Ghent University spin-off, OHMX.bio has always been at the forefront of advanced -omics technology, specializing in cutting-edge discovery and (pre)clinical studies. Joining forces with anacura, a leader in medical and pharmaceutical analytical services, marks a thrilling expansion of our capabilities and market reach.
What this means for our partners and clients:
🔬 Continuation and enhancement of our state-of-the-art next-generation sequencing, advanced bioinformatics, and AI technologies to accelerate discovery and quality control of advanced therapies.
💡 Expanded collaborative opportunities with anacura’s expertise in evidence-based laboratory solutions for healthcare and drug development.
🤝 A shared commitment to quality, scientific excellence, and a personalized approach, ensuring the highest standards of service and innovation.
Both anacura’s CEO Griet Nuytinck and our CEO Gerben Menschaert highlight the strategic fit and shared values between the two companies, emphasizing the benefits of combining their expertise and technologies. The acquisition is seen as a way for both companies to grow, innovate, and strengthen their position in the biotech industry, particularly within the Ghent Biotech ecosystem.
The entire OHMX.bio team is excited about this new journey. We believe that together with anacura, we will solidify our position as a one-stop shop for clients and a market leader in the Ghent Biotech ecosystem and beyond.
Read the full press release through this link: https://lnkd.in/e6GEzHn4
#OHMXbio #Anacura #Acquisition #Biotech #Healthcare #Pharmaceuticals #DrugDiscovery #Diagnostics #Omics